AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. They currently have a GBX 5,600 ($73.63) target price on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price points to a potential upside of 8.36% from the stock’s previous close.
A number of other analysts have also commented on the company. UBS AG set a GBX 4,550 ($59.82) price target on AstraZeneca plc and gave the company a “neutral” rating in a research note on Monday. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Monday. HSBC Holdings plc lifted their price target on AstraZeneca plc from GBX 4,100 ($53.90) to GBX 4,150 ($54.56) and gave the company a “reduce” rating in a research note on Monday. Barclays PLC reissued an “overweight” rating and set a GBX 6,300 ($82.83) price target on shares of AstraZeneca plc in a research note on Thursday, October 5th. Finally, BNP Paribas set a GBX 5,800 ($76.26) price target on AstraZeneca plc and gave the company a “buy” rating in a research note on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 5,113.55 ($67.23).
Shares of AstraZeneca plc (LON AZN) opened at 5168.00 on Wednesday. The company’s market capitalization is GBX 65.43 billion. The firm’s 50-day moving average price is GBX 4,786.58 and its 200 day moving average price is GBX 4,901.67. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.
In related news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($57.45) per share, with a total value of £1,704.30 ($2,240.73).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.